Trial Search Results
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders
To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.
Stanford is currently not accepting patients for this trial.
Collaborator: National Institutes of Health (NIH)
- Procedure: nonmyeloablative allogeneic hematopoietic cell transplant
Inclusion Criteria:- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- HLA matched donor available
Exclusion Criteria:- organ dysfunction
- HIV positive
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study